Related Experiment Video
Updated: Aug 4, 2025

Testing Sensory and Multisensory Function in Children with Autism Spectrum Disorder
Published on: April 22, 2015
Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder
Esraa Shaker1, Osama El Agami1, Abeer Salamah1
1Department of Pediatrics, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt.
Insights
Bumetanide shows promise in treating core symptoms of Autism Spectrum Disorder (ASD). This diuretic improved ASD symptoms in children with minimal side effects, suggesting a potential new therapeutic option.
Area of Science:
- Neurodevelopmental Disorders
- GABAergic Signaling
- Pharmacological Interventions
Background:
- Autism Spectrum Disorder (ASD) is a prevalent neurodevelopmental disorder with unknown pathogenesis.
- Current treatments for core ASD symptoms are limited.
- Altered GABAergic signals are implicated in ASD, and bumetanide affects these pathways.
Purpose of the Study:
- To evaluate the safety and efficacy of bumetanide for treating core symptoms in children with ASD.
Main Methods:
- A 6-month, double-blind, randomized, controlled study involving 80 children (3-12 years) with ASD.
- Participants were assessed using the Childhood Autism Rating Scale (CARS) at baseline and at 1, 3, and 6 months.
- Group 1 received bumetanide, while Group 2 received a placebo.
Main Results:
- Bumetanide significantly improved core ASD symptoms compared to placebo after 6 months (p<0.001).
- Improvements were observed in CARS scores and most sub-items.
- Adverse effects associated with bumetanide were minimal and tolerable.
Conclusions:
- Bumetanide demonstrates a significant role in treating the core symptoms of ASD.
- The drug offers a potentially effective and safe therapeutic option for children with ASD.
Background:
Autism Spectrum Disorder (ASD) is a common child neurodevelopmental disorder, whose pathogenesis is not completely understood. Until now, there is no proven treatment for the core symptoms of ASD. However, some evidence indicates a crucial link between this disorder and GABAergic signals which are altered in ASD. Bumetanide is a diuretic that reduces chloride, shifts gamma-amino-butyric acid (GABA) from excitation to inhibition, and may play a significant role in the treatment of ASD.
Objective:
The objective of this study is to assess the safety and efficacy of bumetanide as a treatment for ASD.
Methods:
Eighty children, aged 3-12 years, with ASD diagnosed by Childhood Autism Rating Scale (CARS), ⩾ 30 were included in this double-blind, randomized, and controlled study. Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1, 3, and 6 months of treatment.
Results:
The use of bumetanide in group 1 improved the core symptoms of ASD in a shorter time with minimal and tolerable adverse effects. There was a statistically significant decrease in CARS and most of its fifteen items in group 1 versus group 2 after 6 months of treatment (p-value <0.001).
Conclusion:
Bumetanide has an important role in the treatment of core symptoms of ASD.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Antihypertensive Drugs: Thiazide-Class Diuretics
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antihypertensive Drugs: Action of Diuretics

